Gregory L Mcintire

US Patent:

8165948, Apr 24, 2012

Filed:

Apr 26, 2010

Appl. No.:

12/767266

Inventors:

James P. O'Shaughnessy - New York NY, US
Gregory L. Cowin - Trumbull CT, US
Stephen M. Downey - Babylon NY, US
Gregory L. McIntire - Stamford CT, US
Kevin P. Tyson - White Plains NY, US

Assignee:

The Globe Resources Group, Inc. - Henderson NV

International Classification:

G06Q 40/00

US Classification:

705 36R, 705 40

Abstract:

The invention is in the field of computer implemented systems and methods for generating a profile of an investor's risk tolerance, providing automated investment allocation advice based on the risk tolerance of the investor, generating at least one list of investments for the portfolio of the investor, allowing for review of the at least one list of investments and information relating to historic and/or hypothetical performance and a description of asset selection methodology, performing automated electronic execution of transactions pertaining the investments, maintenance and monitoring of investment portfolios, and rebalancing of investment portfolios.

US Patent:

8420648, Apr 16, 2013

Filed:

Sep 15, 2011

Appl. No.:

13/233052

Inventors:

Hongna Wang - Fairport NY, US
Stephen R. Davio - Fairport NY, US
Gregory L. McIntire - Florham Park NJ, US
Michael Hall - Albany NY, US
Shazad Suchit - Guilderland NY, US
Jon Summersett - Guilderland NY, US
Brent Whitehead - Piscataway NJ, US

Assignee:

Bausch & Lomb Incorporated - Rochester NY

International Classification:

A61K 31/495

US Classification:

514249, 544353, 5483481

Abstract:

A brimonidine pamoate polymorph exhibits characteristics disclosed herein, wherein the brimonidine pamoate has the following formulaThe polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.

US Patent:

8637514, Jan 28, 2014

Filed:

Mar 14, 2013

Appl. No.:

13/826496

Inventors:

Stephen R. Davio - Fairport NY, US
Gregory L. McIntire - Florham Park NJ, US
Michael Hall - Albany NY, US
Shazad Suchit - Guilderland NY, US
Jon Summersett - Guilderland NY, US
Brent Whitehead - Piscataway NJ, US

Assignee:

Bausch & Lomb Incorporated - Rochester NY

International Classification:

A61K 31/495

US Classification:

514249, 544353

Abstract:

A polymorph of brimonidine pamoate having the formula.

US Patent:

8637515, Jan 28, 2014

Filed:

Mar 14, 2013

Appl. No.:

13/826516

Inventors:

Stephen R. Davio - Fairport NY, US
Gregory L. McIntire - Florham Park NJ, US
Michael Hall - Albany NY, US
Shazad Suchit - Guilderland NY, US
Jon Summersett - Guilderland NY, US
Brent Whitehead - Piscataway NJ, US

Assignee:

Bausch & Lomb Incorporated - Rochester NY

International Classification:

A61K 31/495

US Classification:

514249, 544353

Abstract:

A polymorph of brimonidine pamoate having the formula.

US Patent:

20060257391, Nov 16, 2006

Filed:

May 11, 2005

Appl. No.:

11/126625

Inventors:

Stephen Bartels - New York NY, US
Gregory McIntire - Rochester NY, US
Timothy Comstock - Rochester NY, US
Brian Levy - Rochester NY, US

International Classification:

A61K 38/48

US Classification:

424094640

Abstract:

A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition. Plasmin, microplasmin and miniplasmin are preferred serine proteinase enzymes and plasmin is the most preferred.

US Patent:

20170192025, Jul 6, 2017

Filed:

Mar 24, 2017

Appl. No.:

15/469021

Inventors:

- Baltimore MD, US
Erin Strickland - Greensboro NC, US
Gregory L. McIntire - Greensboro NC, US
Ayodele Morris - Midland TX, US

International Classification:

G01N 33/94
H01J 49/00
G01N 33/493

Abstract:

The present disclosure provides methods for monitoring subject (e.g., patient) adherence to lurasidone therapy, for example as a component of treating a subject for a mental health disorder such as schizophrenia.

US Patent:

20170029866, Feb 2, 2017

Filed:

Jul 29, 2016

Appl. No.:

15/223579

Inventors:

- Baltimore MD, US
Oneka Cummings - Greensboro NC, US
Gregory L. McIntire - Greensboro NC, US

International Classification:

C12Q 1/40

Abstract:

The present disclosure provides methods for monitoring subject (e.g., patient) adherence to Haldol therapy, for example as a component of treating a subject for a mental health disorder such as schizophrenia.

US Patent:

20150168431, Jun 18, 2015

Filed:

Dec 11, 2014

Appl. No.:

14/567935

Inventors:

- Baltimore MD, US
Erin Strickland - Greensboro NC, US
Gregory L. McIntire - Greensboro NC, US
Ayodele Morris - Midland TX, US

International Classification:

G01N 33/94
H01J 49/00

Abstract:

The present disclosure provides methods for monitoring subject (e.g., patient) adherence to lurasidone therapy, for example as a component of treating a subject for a mental health disorder such as schizophrenia.